This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wajcberg, E. Articles by Cersosimo, E. Search for Related Content PubMed PubMed Citation Articles by Wajcberg, E. Articles by Cersosimo, E. Related Collections Lipid Cardiovascular Endocrinology Diabetes and Insulin

Relationship between Vascular Reactivity and Lipids in Mexican-Americans with Type 2 Diabetes Treated with Pioglitazone

Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229

Address all correspondence and requests for reprints to: Eugenio Cersosimo, M.D., Ph.D., Division of Diabetes, Department of Medicine, Mail Code 7886, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: Eugenio.Cersosimo{at}uhs-sa.com.

Context: Vascular dysfunction and insulin resistance precede atherosclerosis in type 2 diabetes (T2DM). Better knowledge of the interaction between these is of considerable clinical interest.

Objective: The objective of this study was to examine the association between inflammation, glucose, and lipid metabolism and vascular dysfunction.

Design and Setting: We conducted a randomized, double-blind, controlled trial of pioglitazone vs. placebo and other therapies aimed at equal glycemic control for 24 wk at an academic tertiary referral clinic.

Patients and Interventions: Mexican-American subjects with T2DM and no complications were randomly assigned to pioglitazone 45 mg daily (PIO, n = 16) or placebo (CON, n = 15) and matched for age, gender, body mass index, diabetes duration, and glycemic control. All subjects completed the study.

Main Outcome Measure: We looked for improved vascular reactivity independent of glycemic control but closely related to plasma adiponectin, lipids, and insulin sensitivity.

Results: After 24 wk, there was an equal decrease in fasting plasma glucose (135 mg/dl), glycosylated hemoglobin (7.0%), and glucose production (15%). The decrease in free fatty acids (30 vs. 10%) and increase in glucose disposal (40 vs. 25%) were greater in PIO vs. CON (P < 0.05). In PIO, plasma high-density lipoprotein rose by 15% (P < 0.05), and low-density lipoprotein and high-density lipoprotein particle size rose significantly (P < 0.01). Plasma adiponectin doubled in PIO (from 6.1 ± 0.8 to 12.7 ± 2.1 µg/ml). Forearm blood flow rose equally (130%) during reactive hyperemia in both groups, although after therapy, the increase was greater (P < 0.001) in PIO (153%) than in CON (137%); vasodilation was greater (P = 0.01) in PIO (92, 160, and 204%) than in CON with acetylcholine (74, 130, and 144%) and with sodium nitroprusside (PIO = 164 and 253% vs. 116 and 230%; P = 0.04). The elevation in diameter was also greater in PIO (13 vs. 10%; P < 0.05). Vascular responses correlated with plasma free fatty acids, adiponectin, and low-density lipoprotein particle size but not with glycemic control.

Conclusion: These data indicate that pioglitazone improves vascular reactivity irrespective of glycemic control and suggest a close association with changes in fat cell metabolism.

This article has been cited by other articles:

				M. Fernandez, C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms Diabetes Care, January 1, 2008; 31(1): 121 - 127. [Abstract] [Full Text] [PDF]